Core Viewpoint - The innovative drug market is not over yet, with numerous catalysts and potential growth opportunities ahead [1][2] Group 1: Market Catalysts - Upcoming academic conferences such as WCLC, ESMO, ASH, and ERS will provide platforms for companies to showcase their latest pipeline data [1] - Continuous disclosure of high-quality data will lead to an increase in pipeline valuations, driving market capitalization and valuations upward [1] Group 2: Market Dynamics - The pharmaceutical sector, particularly innovative drugs, has seen significant gains since the beginning of the year, with rapid rotation within the industry [1] - Short-term fluctuations in core innovative drug targets are primarily influenced by capital flow, with recent adjustments reaching a relative extreme, potentially indicating a bottom or a good entry point for accumulation [1] Group 3: Investment Opportunities - Focus on undervalued segments with growth potential, such as hepatitis B interferon treatment and digital robotics, which are at a critical stage of development [2] - Chain pharmacies are at historical lows and may present future investment opportunities as performance improves and market styles shift [2] - The pharmaceutical industry is characterized by essential demand and long-term growth potential, making it suitable for systematic investment [2]